ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

S Korean pharma laid low by global retreat and Samsung scandal

Scandal compounds grim mood as international partnerships flop

Samsung Bioepis had high hopes for a diabetes biosimilar project with Merck, until the U.S. side canceled the deal. 

SEOUL -- South Korea's pharmaceutical companies are being frozen out of partnerships by major European and U.S. partners, hitting an industry already rocked by the Samsung BioLogics accounting scandal.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more